Arecor Therapeutics PLC

Arecor Therapeutics plc is a clinical-stage biotechnology company based in Little Chesterford, United Kingdom, founded in 2007. It develops therapeutics for diabetes, obesity, and other cardiometabolic diseases. Its lead product candidate, AT278, is a disruptor insulin designed to enhance Automated Insulin Delivery (AID) systems and improve care for people with diabetes. The company is also developing a novel oral delivery platform using a GLP-1 receptor agonist.